Retatrutide: a triple incretin receptor agonist for obesity management

References

• Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205–216. doi: 10.1056/NEJMoa2206038
   PubMed Web of Science ®Google Scholar
• Garvey WT, Frias JP, Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2023;402(10402):613–626. doi: 10.1016/S0140-6736(23)01200-X
   PubMed Web of Science ®Google Scholar
• Perdomo CM, Cohen RV, Sumithran P, et al. Contemporary medical, device, and surgical therapies for obesity in adults. Lancet. 2023;401(10382):1116–1130. doi: 10.1016/S0140-6736(22)02403-5
   PubMed Web of Science ®Google Scholar
• Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989–1002. doi: 10.1056/NEJMoa2032183
   PubMed Web of Science ®Google Scholar
• Davies M, Færch L, Jeppesen OK, et al. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021;397(10278):971–984. doi: 10.1016/S0140-6736(21)00213-0
   PubMed Web of Science ®Google Scholar
• Rubino D, Abrahamsson N, Davies M, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA. 2021;325(14):1414–1425. doi: 10.1001/jama.2021.3224
   PubMed Web of Science ®Google Scholar
• Wadden TA, Bailey TS, Billings LK, et al. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial. JAMA. 2021;325(14):1403–1413. doi: 10.1001/jama.2021.1831
   PubMed Web of Science ®Google Scholar
• Baggio LL, Drucker DJ. Glucagon-like peptide-1 receptor co-agonists for treating metabolic disease. Mol Metab. 2021;46:101090. doi: 10.1016/j.molmet.2020.101090
   PubMed Web of Science ®Google Scholar
• Holst JJ. Incretin hormones and the satiation signal. Int J Obes (Lond). 2013;37(9):1161–1168. doi: 10.1038/ijo.2012.208
   PubMed Web of Science ®Google Scholar
• Frühbeck G, Gómez-Ambrosi J. Control of body weight: a physiologic and transgenic perspective. Diabetologia. 2003;46(2):143–172. doi: 10.1007/s00125-003-1053-4
   PubMed Web of Science ®Google Scholar
• Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. N Engl J Med. 2023;389(6):514–526. doi: 10.1056/NEJMoa2301972
   PubMed Web of Science ®Google Scholar
• Collip JB. Delayed manifestation of the physiological effects of insulin following the administration of certain pancreatic extracts. Am J Physiol. 1923;63(3):391–392.
   Google Scholar
• Schade DS, Woodside W, Eaton RP. The role of glucagon in the regulation of plasma lipids. Metabolism. 1979;28(8):874–886. doi: 10.1016/0026-0495(79)90215-4
   PubMed Web of Science ®Google Scholar
• Fitzpatrick GF, Meguid MM, Gitlitz PH, et al. Glucagon infusion in normal man – effects on 3-methyhistidine excretion and plasma amino acids. Metabolism. 1977;26(5):477–485. doi: 10.1016/0026-0495(77)90091-9
   PubMed Web of Science ®Google Scholar
• Unger RH, Orci L. Essential role of glucagon in pathogenesis of diabetes mellitus. Lancet. 1975;1(7897):14–16. doi: 10.1016/S0140-6736(75)92375-2
   PubMed Web of Science ®Google Scholar
• Gerich JE, Lorenzi M, Schneider V, et al. Effects of somatostatin on plasma glucose and glucagon levels in human diabetes mellitus – pathophysiological and therapeutic implications. New Engl J Med. 1974;291(11):544–547. doi: 10.1056/NEJM197409122911102
   PubMed Web of Science ®Google Scholar
• Gerich JE, Lorenzi M, Schneider V, et al. Inhibition of pancreatic glucagon responses to arginine by somatostatin in normal man and in insulin-dependent diabetics. Diabetes. 1974;23(11):876–880. doi: 10.2337/diab.23.11.876
   PubMed Web of Science ®Google Scholar
• Sakurai H, Dobbs RE, Unger RH. The role of glucagon in the pathogenesis of the endogenous hyperglycemia of diabetes mellitus. Metabolism. 1975;24(11):1287–1297. doi: 10.1016/0026-0495(75)90067-0
   PubMed Web of Science ®Google Scholar
• Holst JJ, Holland W, Gromada J, et al. Insulin and glucagon: partners for life. Endocrinology. 2017;158(4):696–701. doi: 10.1210/en.2016-1748
   PubMed Web of Science ®Google Scholar
• Damond N, Thorel F, Moyers JS, et al. Blockade of glucagon signaling prevents or reverses diabetes onset only if residual β-cells persist. Elife. 2016;5:e13828. doi: 10.7554/eLife.13828
   PubMed Web of Science ®Google Scholar
• Neumann UH, JSS H, Mojibian M, et al. Glucagon receptor gene deletion in insulin knockout mice modestly reduces blood glucose and ketones but does not promote survival. Mol Metab. 2016;5(8):731–736. doi: 10.1016/j.molmet.2016.05.014
   PubMed Web of Science ®Google Scholar
• Schulman JL, Carleton JL, Whitney G, et al. Effect of glucagon on food intake and body weight in man. J Appl Physiol. 1957;11(3):419–421. doi: 10.1152/jappl.1957.11.3.419
   PubMed Web of Science ®Google Scholar
• Salter J. Metabolic effects of glucagon in the wistar rat. Am J Clin Nutr. 1960;8(5):535–539. doi: 10.1093/ajcn/8.5.535
   Web of Science ®Google Scholar
• Salem V, Izzi-Engbeaya C, Coello C, et al. Glucagon increases energy expenditure independently of brown adipose tissue activation in humans. Diab Obes Metab. 2016;18(1):72–81. doi: 10.1111/dom.12585
   PubMed Web of Science ®Google Scholar
• Tan TM, Field BCT, McCullough KA, et al. Coadministration of glucagon-like peptide-1 during glucagon infusion in humans results in increased energy expenditure and amelioration of hyperglycemia. Diabetes. 2013;62(4):1131–1138. doi: 10.2337/db12-0797
   PubMed Web of Science ®Google Scholar
• Wynne K, Park AJ, Small CJ, et al. Subcutaneous oxyntomodulin reduces body weight in overweight and obese subjects – a double-blind, randomized, controlled trial. Diabetes. 2005;54(8):2390–2395. doi: 10.2337/diabetes.54.8.2390
   PubMed Web of Science ®Google Scholar
• Wynne K, Park AJ, Small CJ, et al. Oxyntomodulin increases energy expenditure in addition to decreasing energy intake in overweight and obese humans: a randomised controlled trial. Int J Obes. 2006;30(12):1729–1736. doi: 10.1038/sj.ijo.0803344
   PubMed Web of Science ®Google Scholar
• Pi-Sunyer X, Astrup A, Fujioka K, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New Engl J Med. 2015;373(1):11–22. doi: 10.1056/NEJMoa1411892
   PubMed Web of Science ®Google Scholar
• Rosen CJ, Ingelfinger JR. Shifting tides offer new hope for obesity. N Engl J Med. 2022;387(3):271–273. doi: 10.1056/NEJMe2206939
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Frias J, Jastreboff AM, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet. 2023;402(10401):529–544. doi: 10.1016/S0140-6736(23)01053-X
   PubMed Web of Science ®Google Scholar
• Davies MJ, Aroda VR, Collins BS, et al. Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the american diabetes Association (ADA) and the European Association for the study of diabetes (EASD). Diabetologia. 2022;65(12):1925–1966. doi: 10.1007/s00125-022-05787-2
   PubMed Web of Science ®Google Scholar
• Knerr PJ, Mowery SA, Douros JD, et al. Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice. Mol Metab. 2022;63:101533. doi: 10.1016/j.molmet.2022.101533
   PubMed Web of Science ®Google Scholar
• Frias JP, Deenadayalan S, Erichsen L, et al. Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial. Lancet. 2023;402(10403):720–730. doi: 10.1016/S0140-6736(23)01163-7
   PubMed Web of Science ®Google Scholar
• Lorenz M, Lawson F, Owens D, et al. Differential effects of glucagon-like peptide-1 receptor agonists on heart rate. Cardiovasc Diabetol. 2017;16(1):6. doi: 10.1186/s12933-016-0490-6
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. A study of retatrutide (LY3437943) in participants with obesity and cardiovascular disease (TRIUMPH-3). [cited 2023 Oct 6]. Available at: https://classic.clinicaltrials.gov/ct2/show/NCT05882045
   Google Scholar
• Exclusive: most patients using weight-loss drugs like wegovy stop within a year, data show. Reuters. [cited Oct 6, 2023]. Available from: https://www.reuters.com/business/healthcare-pharmaceuticals/most-patients-using-weight-loss-drugs-like-wegovy-stop-within-year-data-show-2023-07-11/
   Google Scholar
• Levi J, Wang J, Venter F, et al. Estimated minimum prices and lowest available national prices for antiobesity medications: improving affordability and access to treatment. Obesity. 2023;31(5):1270–1279. (Silver Spring). doi: 10.1002/oby.23725
   PubMed Web of Science ®Google Scholar
• Nauck MA, Quast DR, Wefers J, et al. The evolving story of incretins (GIP and GLP-1) in metabolic and cardiovascular disease: a pathophysiological update. Diab Obes Metab. 2021;23(S3):5–29. doi: 10.1111/dom.14496
   PubMedGoogle Scholar
• Murthy SN, Ganiban G. Effect of the secretin family of peptides on gastric emptying and small intestinal transit in rats. Peptides. 1988;9(3):583–588. doi: 10.1016/0196-9781(88)90168-4
   PubMed Web of Science ®Google Scholar
• Urva S, O’Farrell L, Du Y, et al. The novel GIP, GLP-1 and glucagon receptor agonist retatrutide delays gastric emptying. Diab Obes Metab. 2023;25(9):2784–2788. doi: 10.1111/dom.15167
   PubMed Web of Science ®Google Scholar
• Urva S, Coskun T, Loghin C, et al. The novel dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long-acting GLP-1 receptor agonists. Diab Obes Metab. 2020;22(10):1886–1891. doi: 10.1111/dom.14110
   PubMed Web of Science ®Google Scholar
• Maselli D, Atieh J, Clark MM, et al. Effects of liraglutide on gastrointestinal functions and weight in obesity: a randomized clinical and pharmacogenomic trial. Obesity. 2022;30(8):1608–1620. doi: 10.1002/oby.23481
   PubMed Web of Science ®Google Scholar
• American Society of Anesthesiologists. Consensus-based guidance on preoperative management of patients (adults and children) on glucagon-like peptide-1 (GLP-1) receptor agonists. [cited Oct 6, 2023]. Available at: https://www.asahq.org/about-asa/newsroom/news-releases/2023/06/american-society-of-anesthesiologists-consensus-based-guidance-on-preoperative
   Google Scholar
• Jalleh RJ, Jones KL, Rayner CK, et al. Normal and disordered gastric emptying in diabetes: recent insights into (patho)physiology, management and impact on glycaemic control. Diabetologia. 2022;65(12):1981–1993. doi: 10.1007/s00125-022-05796-1
   PubMed Web of Science ®Google Scholar
• van Ruiten CC, Ten Kulve JS, van Bloemendaal L, et al. Ijzerman RG: eating behavior modulates the sensitivity to the central effects of GLP-1 receptor agonist treatment: a secondary analysis of a randomized trial. Psychoneuroendocrinology. 2022;137:105667. doi: 10.1016/j.psyneuen.2022.105667
   PubMed Web of Science ®Google Scholar
• Nicolau J, Pujol A, Tofé S, et al. Short term effects of semaglutide on emotional eating and other abnormal eating patterns among subjects living with obesity. Physiol Behav. 2022;257:113967. doi: 10.1016/j.physbeh.2022.113967
   PubMedGoogle Scholar
• Wharton S, Batterham RL, Bhatta M, et al. Two-year effect of semaglutide 2.4 mg on control of eating in adults with overweight/obesity: STEP 5. Obesity. 2023;31(3):703–715. (Silver Spring). doi: 10.1002/oby.23673
   PubMed Web of Science ®Google Scholar
• Geisler CE, Antonellis MP, Trumbauer W, et al. Tirzepatide suppresses palatable food intake by selectively reducing preference for fat in rodents. Diab Obes Metab. 2023;25(1):56–67. doi: 10.1111/dom.14843
   PubMed Web of Science ®Google Scholar
• Novo Nordisk. Semaglutide 2.4 mg reduces the risk of major adverse cardiovascular events by 20% in adults with overweight or obesity in the SELECT trial. [cited 2023 Oct 6]. Available at: https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=166301
   Google Scholar
• Kosiborod MN, Abildstrøm SZ, Borlaug BA, et al. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med. 2023;389(12):1069–1084. doi: 10.1056/NEJMoa2306963
   PubMed Web of Science ®Google Scholar
• Anker SD, Usman MS, Butler J. SGLT2 inhibitors: from antihyperglycemic agents to all-around heart failure therapy. Circulation. 2022;146(4):299–302. doi: 10.1161/CIRCULATIONAHA.122.060348
   PubMed Web of Science ®Google Scholar
• Saponaro C, Pattou F, Bonner C. SGLT2 inhibition and glucagon secretion in humans. Diabetes metab. 2018;44(5):383–385. doi: 10.1016/j.diabet.2018.06.005
   PubMed Web of Science ®Google Scholar
• Bao P, Zhang Z, Liang Y, et al. Role of the gut microbiota in glucose Metabolism during heart failure. Front Cardiovasc Med. 2022;9:903316. doi: 10.3389/fcvm.2022.903316
   PubMed Web of Science ®Google Scholar
• Gao C, Ren SV, Yu J, et al. Glucagon Receptor Antagonism Ameliorates Progression of Heart Failure. JACC Basic Transl Sci. 2019;4(2):161–172. doi: 10.1016/j.jacbts.2018.11.001
   PubMedGoogle Scholar
• Horton JL, Davidson MT, Kurishima C, et al. The failing heart utilizes 3-hydroxybutyrate as a metabolic stress defense. JCI Insight. 2019;4(4):e124079. doi: 10.1172/jci.insight.124079
   PubMed Web of Science ®Google Scholar
• Karwi QG, Zhang L, Wagg CS, et al. Targeting the glucagon receptor improves cardiac function and enhances insulin sensitivity following a myocardial infarction. Cardiovasc Diabetol. 2019;18(1):1. doi: 10.1186/s12933-019-0806-4
   PubMedGoogle Scholar
• Aranda-Domene R, Orenes-Piñero E, Arribas-Leal JM, et al. Evidence for a lack of inotropic and chronotropic effects of glucagon and glucagon receptors in the human heart. Cardiovasc Diabetol. 2023;22(1):128. doi: 10.1186/s12933-023-01859-8
   PubMed Web of Science ®Google Scholar
• Lindsay RT, Ambery P, Jermutus L, et al. Glucagon and exenatide improve contractile recovery following ischaemia/reperfusion in the isolated perfused rat heart. Physiol Rep. 2023;11(6):e15597. doi: 10.14814/phy2.15597
   PubMed Web of Science ®Google Scholar
• Li AL, Lian L, Chen XN, et al. The role of mitochondria in myocardial damage caused by energy metabolism disorders: from mechanisms to therapeutics. Free Radic Biol Med. 2023;208:236–251. doi: 10.1016/j.freeradbiomed.2023.08.009
   PubMed Web of Science ®Google Scholar
• World Obesity Federation. World Obesity Atlas 2023. [cited 2023 Oct 6]. Available at: https://data.worldobesity.org/publications/?cat=19
   Google Scholar